P@'{;9>==%4BYF@8KJ#7%R<?1I7GP
SYSTEM PROCESSING...
P@'{;9>==%4BYF@8KJ#7%R<?1I7GP
SYSTEM PROCESSING...
Posted: 2025-06-11 14:00:15 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-06-11 14:00:40 UTC
Verified By
Rollup News
$ABCL is developing a platform to cure virtually any disorder by mastering the creation of highly specific antibodies, potentially evolving into the $PLTR of biotech. The company's platform has expanded beyond viral antibodies to control almost any biological process, with recent clinical trial approvals for ABCL575 and ABCL635. Despite significant progress, financials remain a risk.
Platform for curing disorders via specific antibodies
Expansion beyond viral antibodies to control biological processes
Clinical trial approvals for ABCL575 and ABCL635
Potential to become the $PLTR of biotech
Financials remain abysmal, making it a risky investment
Need to become cash flow positive
Clinical trial success is crucial